

ENDURING MATERIAL LEARNER NOTIFICATION

MED Learning Group

The DETECT Initiative in Early Alzheimer's Disease: Optimizing Collaboration and Multidisciplinary Care to Facilitate Timely Diagnosis

March 20, 2023 – March 20, 2024

Online

Acknowledgement of Financial Commercial Support

Eli Lilly

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-23-023-H01-P / JA4008163-9999-23-023-H01-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate the burden of Alzheimer's disease (AD), including the process of prolonged decline in cognitive function.
2. Provide an accurate and timely diagnosis of AD to allow for early disease management and/or referral to specialists.
3. Use cognitive assessments, biomarkers, and imaging in distinguishing between normal aging and cognitive impairment.
4. Select and use the best therapeutic options for patients with AD based on up-to-date clinical data on established and emerging disease-modifying therapies.
5. Employ best practices for multidisciplinary care coordination, workflows, and best practices for referral of patients.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
------------	-----------	-----------------------------------

Liana	Apostolova	Biogen, IQVIA, NIH, Lilly, Eisai, GE HealthCare, Roche Diagnostics, Genentech, Corium, Siemens: Consultant; Avid Radiopharmaceuticals, Life Molecular Imaging, Roche: Contracted Research; Cassava Sciences: Stock Shareholder
Daniel	DaSilva	NA
Matthew	Frese	NA
Christina	Gallo	NA
Nicole	Longo	NA
Jessica	McMullen	NA
Jo	Shultz	NA
Geoffrey C.	Wall	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com